An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes.
about
The impact of GPCR structures on pharmacology and structure-based drug designPyrrolamide DNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening To Identify Antibacterial AgentsBiophysical Fragment Screening of the β 1 -Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug DesignLarge scale meta-analysis of fragment-based screening campaigns: privileged fragments and complementary technologiesFragment-based screening using surface plasmon resonance technology.Unique identifiers for small molecules enable rigorous labeling of their atoms.Postgenomic strategies in antibacterial drug discovery.Melanocortin-3 receptors and metabolic homeostasis.Screening of protein-protein interaction modulators via sulfo-click kinetic target-guided synthesisDesign of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics.Virtual fragment screening: exploration of MM-PBSA re-scoring.The essential roles of chemistry in high-throughput screening triageAdvances in fragment-based drug discovery platforms.Fragment-based lead discovery on G-protein-coupled receptors.The importance of molecular complexity in the design of screening libraries.Saturation transfer difference NMR for fragment screening.A fluorescent approach for identifying P2X1 ligandsTwenty years on: the impact of fragments on drug discovery.Computational medicinal chemistry in fragment-based drug discovery: what, how and when.Progress in structure based drug design for G protein-coupled receptors.The influence of the 'organizational factor' on compound quality in drug discovery.Bacterial DNA replication enzymes as targets for antibacterial drug discovery.Structure-based and fragment-based GPCR drug discovery.Fragment-based lead discovery: challenges and opportunities.Fragment-based screening by biochemical assays: Systematic feasibility studies with trypsin and MMP12.Correction for interference by test samples in high-throughput assays.Prediction of Positions of Active Compounds Makes It Possible To Increase Activity in Fragment-Based Drug Development.ClogP(alk): a method for predicting alkane/water partition coefficient.Ligand efficiency metrics in drug discovery: the pros and cons from a practical perspective.Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors
P2860
Q24628661-19A594F4-3296-4700-9FC4-A2CE504008FCQ27676314-A66D7D12-7C9C-4550-9298-C30D576D939FQ27676919-8032A6B6-6437-459B-B5D8-8D0C1C76E751Q27697268-CAE165CD-6368-4FE7-A818-1FD361B2ECA7Q33436591-07B1E0B0-DFE7-4037-87E5-6DD859567D9FQ33718167-7ED0C033-447D-4A43-A661-1E5E058AB90DQ33745572-D4F421ED-5484-4561-8B43-DAA4C90BF6B4Q33782186-D4C80E99-2FFB-4699-B570-7B0DB64C868BQ33877498-40B71EF4-B62A-4958-A3B5-7036F9444D17Q33908733-4ABADCE5-2CBC-4CAA-ACF0-90BDC4CFADDCQ34368348-A194AFA9-3356-4ECE-ABB1-5028BB960628Q34435458-72670118-10C9-498B-AC7D-8E3608AA7A6CQ34616682-39746B6C-8A83-4363-A55B-2BAA4303695FQ34690000-402822AE-909A-47A8-ABDA-73B80771BFB6Q35016524-41A12979-5699-41B8-A849-6F65DC93A7DDQ35082073-36EE12AF-C824-4AA6-8A6E-64B62FC84FEBQ35647162-B47647DC-70F5-4AB5-892B-EBC0BBBA88C1Q36078186-C8454AA1-5CD0-481F-85C0-FC4BB229EB18Q37856296-312E2259-A770-4DF0-AD4E-39A836FA462FQ37880053-D2E03A70-6E96-46F5-B0AC-821F3CA7577DQ37940789-B0C42250-E0A0-4136-8943-64AA2BF0401EQ37998090-5AFAD9CE-E06E-4409-BF8D-05C34771B6FFQ38172457-2071079C-043E-4D64-BD04-57456D9E5C95Q39731911-D1CEB363-060C-405B-A684-A55BE91DD520Q42882505-A431D5FB-F36F-4A15-863D-E51C6FC6765BQ45154816-0FCDB711-6C4B-4EF9-A196-33EE356E2736Q46065964-BB60E547-674E-4768-BB29-7664A827D6DBQ50181313-3BDF1FC1-F1DA-4337-9E02-242FC15A7D50Q50502203-96B30E01-549C-4E24-8D52-871AC26E9AEEQ58759036-6FFDED98-43FF-42D5-9622-8922AFFB54BB
P2860
An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
An integrated approach to frag ...... a's drug discovery programmes.
@ast
An integrated approach to frag ...... a's drug discovery programmes.
@en
type
label
An integrated approach to frag ...... a's drug discovery programmes.
@ast
An integrated approach to frag ...... a's drug discovery programmes.
@en
prefLabel
An integrated approach to frag ...... a's drug discovery programmes.
@ast
An integrated approach to frag ...... a's drug discovery programmes.
@en
P2093
P50
P1476
An integrated approach to frag ...... a's drug discovery programmes.
@en
P2093
Alastair J H Brown
Ed J Griffen
Hitesh Sanganee
Jeffrey S Albert
Lise-Lotte Olsson
Peter W Kenny
Philip D Edwards
Rutger H A Folmer
Stefan Geschwindner
Thorsten Nowak
P304
P356
10.2174/156802607782341091
P577
2007-01-01T00:00:00Z